Phase 3 Recruiting Academic/Other
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …
Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in California: - Kaiser Permanente-Deer Valley Medical Center — Antioch, California
- Tower Cancer Research Foundation — Beverly Hills, California
- Kaiser Permanente Dublin — Dublin, California
- Kaiser Permanente-Fremont — Fremont, California
- Washington Hospital — Fremont, California
Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in California: - Kaiser Permanente-Anaheim — Anaheim, California
- Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- Kaiser Permanente-Baldwin Park — Baldwin Park, California
- Kaiser Permanente-Bellflower — Bellflower, California
- Tower Cancer Research Foundation — Beverly Hills, California
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary s…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06931340
Sites in California: - Kaiser Permanente Dublin — Dublin, California
- Kaiser Permanente-Fremont — Fremont, California
- Kaiser Permanente Fresno Orchard Plaza — Fresno, California
- UC San Diego Moores Cancer Center — La Jolla, California
- Kaiser Permanente- Modesto MOB II — Modesto, California
Phase 3 Recruiting Network
This phase III trial compares the effect of adding carboplatin to the standard of care chemotherapy drug cabazitaxel versus cabazitaxel alone in treating prostate cancer that keeps growing even when the amount of testosterone in the body i…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06470243
Sites in California: - Tibor Rubin VA Medical Center — Long Beach, California
Phase 3 Recruiting Industry
The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans or dea…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07225946
Sites in California: - MemorialCare Orange Coast Medical Center — Fountain Valley, California
- University Of California San Diego — La Jolla, California
- Cancer and Blood Specialty Clinic — Los Alamitos, California
- USC Norris Comprehensive Cancer Center — Los Angeles, California
- Valkyrie Clinical Trials — Los Angeles, California
Phase 3 Recruiting Industry
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136624
Sites in California: - University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040) — Orange, California
- Stanford Cancer Center ( Site 0036) — Palo Alto, California
- Kaiser Permanente Riverside Medical Center ( Site 0099) — Riverside, California
Phase 3 Recruiting Network
This study is being done to answer the following question: Is the strategy to give higher doses of radiotherapy treatment over a shorter period of time using special equipment and fewer treatments (also known as Stereotactic Body Radiation…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06235697
Sites in California: - Kaiser Permanente-Deer Valley Medical Center — Antioch, California
- Kaiser Permanente Dublin — Dublin, California
- Kaiser Permanente-Fremont — Fremont, California
- Kaiser Permanente Fresno Orchard Plaza — Fresno, California
- Kaiser Permanente-Fresno — Fresno, California
Phase 3 Recruiting Industry
The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).
Sponsor: Amgen
NCT ID: NCT07213674
Sites in California: - City of Hope National Medical Center — Duarte, California
- City of Hope Orange County Lennar Foundation Cancer Center — Duarte, California
- Providence Saint Jude Medical Center — Fullerton, California
- University of California Irvine — Orange, California
- University of California San Francisco — San Francisco, California
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. Th…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05939414
Sites in California: - VA Greater LA Healthcare System — Los Angeles, California
- VA Palo Alto Health Care System — Palo Alto, California
- Stanford University — Palo Alto, California
- UCSF — San Francisco, California
Phase 3 Recruiting Industry
The purpose of this study is to determine whether \[225Ac\]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus androgen receptor pathway inhibitor (ARPI), improves the radiographic progression f…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06855277
Sites in California: - Univ Cali Irvine ALS Neuromuscular — Orange, California
- Stanford University Medical Center — Palo Alto, California
- Sansum Clinic — Santa Barbara, California
Phase 2, Phase 3 Recruiting Industry
This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA ta…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06780670
Sites in California: - VA Greater LA Healthcare System — Los Angeles, California
- VA Palo Alto Health Care System — Palo Alto, California
- Stanford University Medical Center — Palo Alto, California
- Sansum Clinic — Santa Barbara, California
- Saint Johns Cancer Institute — Santa Monica, California
Phase 3 Recruiting Industry
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Sponsor: Clarity Pharmaceuticals Ltd
NCT ID: NCT06056830
Sites in California: - Urology Group of Southern California — Los Angeles, California
- Greater Los Angeles VA Medical Center — Los Angeles, California
- UC Irvine Health — Orange, California
- Stanford University Medical Center — Stanford, California
Phase 3 Recruiting Industry
The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC.
Sponsor: AstraZeneca
NCT ID: NCT07611110
Sites in California: - Research Site — Duarte, California
- Research Site — Irvine, California
- Research Site — Newport Beach, California
- Research Site — San Francisco, California
Phase 2, Phase 3 Recruiting Federal
This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival…
Sponsor: VA Office of Research and Development
NCT ID: NCT04787744
Sites in California: - VA Long Beach Healthcare System, Long Beach, CA — Long Beach, California
- VA Greater Los Angeles Healthcare System, West Los Angeles, CA — West Los Angeles, California
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with Androgen Receptor Pathway Inhibitor Treatment
Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
NCT ID: NCT06520345
Sites in California: - Chao Family Comprehensive Cancer Centre — Orange, California
Phase 3 Recruiting Academic/Other
The purpose of this study is to compare whether the FDA and Health Canada approved microUS is as effective as the currently used option (MRI) for imaging the prostate gland. Participants will be randomized into two groups to compare the im…
Sponsor: University of Alberta
NCT ID: NCT06626022
Sites in California: - University of California, Los Angeles (UCLA) — Los Angeles, California
Phase 3 Recruiting Academic/Other
With people living longer after being treated for prostate cancer, quality of life has become a concern when considering the treatment plan. Sometimes after radiation therapy, patients may experience problems that affect the urinary and bo…
Sponsor: Jonsson Comprehensive Cancer Center
NCT ID: NCT07293585
Sites in California: - University of California at Los Angeles — Los Angeles, California
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in California: - University of California Irvine Chao Family Comprehensive Cancer Center — Irvine, California
- University of San Diego Moores Cancer Center — La Jolla, California
- UCLA Jonsson Comprehensive Cancer Center — Los Angeles, California
- USC Norris Comprehensive Cancer Center — Los Angeles, California
Phase 2 Recruiting Industry
A multicenter, open-label, prospective study to investigate immune boost response changes in patients with metastatic castrate-resistant prostate cancer (mCRPC).
Sponsor: Dendreon
NCT ID: NCT06134232
Sites in California: - City of Hope - National Medical Center — Duarte, California
- Urology Associates of Central California Medical Group — Fresno, California
- Unio Health Partners - Genesis Research, LLC — San Diego, California
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
Sponsor: DualityBio Inc.
NCT ID: NCT05914116
Sites in California: - Research Site 125 — Los Angeles, California
- Research Site 133 — Los Angeles, California
- Research Site 103 — Los Angeles, California
- Research Site 128 — Santa Monica, California
Phase 1, Phase 2 Recruiting Industry
The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug\[s\]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab. The study has…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT03972657
Sites in California: - John Wayne Cancer Institute (JWCI) — Santa Monica, California
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants with mCRPC …
Sponsor: Kyntra Bio
NCT ID: NCT06842498
Sites in California: - VA Greater Los Angeles Healthcare System — Los Angeles, California
- UCLA Clark Urology Center — Los Angeles, California
- University of California San Francisco — San Francisco, California
Phase 2 Recruiting Federal
This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use ola…
Sponsor: VA Office of Research and Development
NCT ID: NCT04038502
Sites in California: - VA Greater Los Angeles Healthcare System, West Los Angeles, CA — West Los Angeles, California
Phase 2 Recruiting Industry
This is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC who have progressed on prior abiraterone by PCWG3 criteria. Disease must have progressed on…
Sponsor: Zenith Epigenetics
NCT ID: NCT04986423
Sites in California: - California Research Institute — Los Angeles, California
- University of California, San Francisco — San Francisco, California
- Innovative Clinical Research Institute — Whittier, California
Phase 1, Phase 2 Recruiting Industry
This study is researching an investigational drug called REGN4336 both alone or together with another investigational drug called REGN5678. The study is focused on participants with previously treated metastatic prostate cancer. The main p…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT05125016
Sites in California: - Stanford University Medical Center - Blake Wilbur Drive — Palo Alto, California